What is the structural and mechanistic difference between Humanin and SS-31?

Humanin and SS-31 are both mitochondria-associated peptides but have distinct structural origins and mechanisms. Humanin is a 21-amino acid peptide encoded within the 16S rRNA gene of the mitochondrial genome, making it one of the originally identified mitochondrially-derived peptides (MDPs). Its primary studied mechanisms include extracellular receptor engagement (FPRL1/ALK receptor complex) to inhibit apoptosis, cytoprotective effects in neuronal and cardiac cell models via JAK2/STAT3 signaling, and modulation of IGF binding protein-3. SS-31 (elamipretide), by contrast, is a synthetic tetrapeptide (D-Arg-2'6'-Dmt-Lys-Phe-NH2) designed to selectively accumulate in the inner mitochondrial membrane through electrostatic and aromatic interactions with cardiolipin — a phospholipid essential to electron transport chain organization. SS-31 acts intramembrane to stabilize cardiolipin, reduce ROS production, and preserve ATP synthesis efficiency under oxidative stress. These distinct mechanisms make them complementary rather than interchangeable research tools in mitochondrial biology investigations.

What clinical trials exist for SS-31 (elamipretide)?

SS-31 (elamipretide, developed by Stealth BioTherapeutics) has advanced through the most extensive human clinical trial program of any mitochondrially-targeted peptide. Phase 1 trials established pharmacokinetics and tolerability. Phase 2 trials examined multiple indications: Barth syndrome (a rare mitochondrial cardiomyopathy caused by cardiolipin synthase mutations), primary mitochondrial myopathy (MMPOWER trial), and heart failure with reduced ejection fraction (TESARO program). The Barth syndrome Phase 2 program produced positive results demonstrating functional improvement on the 6-minute walk test in this rare pediatric population. The MMPOWER Phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoint. The TESARO heart failure program showed preliminary left ventricular function improvements in Phase 2, with Phase 3 progression affected by Stealth BioTherapeutics entering financial restructuring in 2022. Elamipretide remains investigational and is not FDA-approved as of 2026.

How do mitochondria-targeting peptides differ mechanistically from conventional antioxidants?

Conventional antioxidant compounds — including vitamin E, vitamin C, and coenzyme Q10 — function through generalized free radical scavenging distributed throughout cellular compartments. Their ability to reach the mitochondrial inner membrane, where the majority of reactive oxygen species (ROS) are generated during oxidative phosphorylation, is limited by lipid membrane partitioning and concentration gradients that restrict mitochondrial accumulation. Mitochondrially-targeted peptides like SS-31 are designed to overcome this limitation through structural features that drive preferential mitochondrial concentration. SS-31's alternating charged and aromatic amino acids enable selective binding to the negatively charged, cardiolipin-rich inner mitochondrial membrane, concentrating the compound at the primary ROS generation site rather than distributing it throughout cellular water. This compartment-specific mechanism allows mitochondria-targeting peptides to modulate electron transport chain function, reduce ROS at the source, and preserve membrane architecture in ways that systemically distributed antioxidants cannot replicate — a distinction consistently observed in head-to-head preclinical model comparisons.

Humanin and SS-31: Mitochondria-Targeting Peptides in Anti-Aging Research

Humanin and SS-31 (elamipretide) represent two structurally distinct classes of mitochondria-targeting peptides that have attracted significant research interest for their roles in cytoprotection and age-related cellular dysfunction. This post summarizes peer-reviewed scientific findings on their mechanisms of action, relevant animal model data, and available clinical trial evidence — all material is presented for research reference only and does not constitute medical advice or guidance for human use.

Humanin: A Mitochondrially Encoded Cytoprotective Peptide

Discovery and Genomic Origin

Humanin (HN) is a 21-amino-acid peptide first identified in 2001 by Hashimoto et al. (Proceedings of the National Academy of Sciences, 2001) through a functional screen of cDNA libraries from surviving neurons in Alzheimer's disease-affected brain tissue. Unusually for a signaling peptide, Humanin is encoded within the 16S ribosomal RNA gene of the mitochondrial genome, a region of mitochondrial DNA not previously associated with protein-coding function in humans.

This mitochondrial genomic origin places Humanin in a growing class of mitochondria-derived peptides (MDPs), a family that also includes MOTS-c and SHLPs (small humanin-like peptides), all of which appear to participate in retrograde signaling between mitochondria and the nucleus or extracellular environment.

Cytoprotective Signaling Pathways

Humanin exerts cytoprotective effects through multiple receptor-mediated and intracellular pathways, a mechanistic complexity that has been the subject of extensive investigation.

STAT3 Activation

Research from the Cohen laboratory at USC has demonstrated that Humanin activates the JAK2/STAT3 signaling pathway through interaction with a tripartite receptor complex consisting of the ciliary neurotrophic factor receptor alpha (CNTFRα), WSX-1 (IL-27Rα), and gp130 (Kim et al., PLoS ONE, 2010). STAT3 phosphorylation downstream of this complex promotes transcription of anti-apoptotic genes including Bcl-2 and Bcl-xL, providing a mechanistic explanation for the neuroprotective effects observed in cell models of Alzheimer's-related amyloid toxicity.

MAPK/ERK Pathway

Independent of STAT3 activation, Humanin has been shown to engage the MAPK/ERK survival pathway in neuronal and cardiac cell lines. Muzumdar et al. (FASEB Journal, 2009) demonstrated that Humanin activates ERK1/2 phosphorylation in hypothalamic neurons, leading to downstream effects on insulin sensitivity and glucose metabolism — findings that implicated Humanin in metabolic regulation beyond its initially described neuroprotective role.

IGF Binding Protein-3 Interaction

A notable binding partner for Humanin is insulin-like growth factor binding protein-3 (IGFBP-3), a protein that modulates IGF-1 bioavailability and has independent pro-apoptotic activity. Ikonen et al. (Proceedings of the National Academy of Sciences, 2003) showed that Humanin binds directly to IGFBP-3 and blocks its ability to induce apoptosis in hematopoietic cells, identifying a mechanism through which Humanin may modulate IGF axis signaling and cellular survival in multiple tissue types.

Humanin and Aging

Circulating Humanin levels have been reported to decline with age in both rodent and human studies, a finding that has generated interest in Humanin as a biomarker of biological aging and mitochondrial function. Muzumdar et al. (Aging, 2010) observed that centenarians and their offspring exhibited higher circulating Humanin levels compared to age-matched controls without familial longevity, suggesting a potential link between Humanin signaling and exceptional longevity phenotypes.

Animal studies using Humanin-deficient mouse models have shown accelerated age-related metabolic decline, increased oxidative stress markers, and reduced lifespan, providing genetic evidence for Humanin's role in organismal aging (Gong et al., Aging Cell, 2018).

SS-31 (Elamipretide): Cardiolipin-Targeting Szeto-Schiller Peptide

Structure and Mechanism of Action

SS-31, also known as elamipretide, is a tetrapeptide (D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2) developed by Hazel Szeto and Peter Schiller at Cornell University. It is the lead compound of the Szeto-Schiller (SS) peptide class, a family of aromatic cationic peptides designed to selectively accumulate in the inner mitochondrial membrane.

The primary molecular target of SS-31 is cardiolipin, a dimeric phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin plays essential roles in organizing the mitochondrial electron transport chain (ETC) supercomplexes and stabilizing cytochrome c in its electron carrier conformation. Szeto et al. (Annals of the New York Academy of Sciences, 2011) demonstrated that SS-31 intercalates into cardiolipin-containing membranes and prevents cardiolipin peroxidation, thereby preserving ETC complex activity and reducing reactive oxygen species (ROS) generation.

Mitochondrial Bioenergetics Effects

By protecting cardiolipin from oxidative damage, SS-31 preserves the structural integrity of ETC supercomplexes (particularly Complex I-III assemblies) and maintains the mitochondrial membrane potential necessary for efficient oxidative phosphorylation. Birk et al. (Cell Metabolism, 2013) showed in isolated cardiomyocytes and in vivo cardiac ischemia-reperfusion models that SS-31 restored ATP synthesis rates and reduced infarct size following ischemic injury, findings attributed to preserved cristae morphology and respiratory chain efficiency.

MMPOWER-HF Clinical Trial

The most significant clinical translation of SS-31 research to date is the MMPOWER-HF trial (MitoTARGET), a Phase II randomized controlled trial evaluating elamipretide in patients with heart failure with reduced ejection fraction (HFrEF).

Daubert et al. (JACC Heart Failure, 2017) reported results from the MMPOWER-HF trial involving 36 patients randomized to elamipretide or placebo. The primary endpoint was change in 6-minute walk distance at 4 weeks. While the trial showed favorable trends in exercise capacity and patient-reported outcomes, it did not meet its primary endpoint with statistical significance in the full population. Secondary analyses suggested improvements in patient-reported outcomes on the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the elamipretide group.

A follow-on open-label extension study (MMPOWER-3) enrolled patients from the original trial in a longer-duration treatment cohort, with results suggesting durable effects on functional capacity over 36 weeks in a subset of patients. These data have been used to support ongoing larger Phase III development efforts.

Age-Related Mitochondrial Dysfunction

Beyond cardiac applications, SS-31 has been studied in preclinical models of age-related mitochondrial dysfunction across multiple tissues. Siegel et al. (Aging Cell, 2013) demonstrated in aged rat skeletal muscle that SS-31 treatment improved mitochondrial respiration rates, reduced oxidative damage markers, and partially reversed the age-related decline in ETC complex activity — findings that have stimulated interest in SS-31 as a research tool for studying the mitochondrial theory of aging.

Renal aging studies have also documented protective effects of SS-31 on glomerular architecture and tubular mitochondrial morphology in aged mice (Sweetwyne et al., Journal of the American Society of Nephrology, 2017), extending the tissue range of observed preclinical effects.

Shared Research Themes: MDPs and Mitochondrial Communication

Both Humanin and SS-31 illustrate a broader conceptual shift in how mitochondria are understood in cellular biology: not merely as passive energy generators but as active signaling organelles that communicate with the nucleus, plasma membrane, and extracellular environment via peptides, metabolites, and membrane-derived vesicles.

The mitochondria-derived peptide (MDP) concept, formalized by Bhupinder Bhanu and colleagues at USC, frames Humanin and its relatives as part of a mitochondrial stress response system that coordinates cellular adaptation to metabolic challenge, oxidative stress, and aging. SS-31, while synthetic rather than endogenous, targets the same cardiolipin-centered hub of mitochondrial membrane architecture.

For further context on related compounds, see the MOTS-c research entry in this database.

All content on ClinicalPeptide.org is intended exclusively for research reference. No content constitutes medical advice, clinical guidance, or recommendations for human use.